FTSE 100: Index falls as earnings results weigh; pound below $1.33, Bodycote soars
Iradimed Corporation (NASDAQ:IRMD), a medical device company with a market capitalization of $736 million and an impressive gross profit margin of 77%, announced the results of its annual meeting of stockholders held Thursday. The company, which has demonstrated strong financial health according to InvestingPro analysis, presented three proposals to stockholders.
First, the election of directors was approved. Roger Susi, Monty Allen, Anthony Vuoto, Hilda Scharen-Guivel, and James Hawkins (NASDAQ:HWKN) were each elected to the company's board of directors. The votes for each director were as follows: Susi received 8,851,894 votes for and 2,226,129 votes withheld; Allen received 9,535,898 votes for and 1,542,125 votes withheld; Vuoto received 10,760,158 votes for and 317,865 votes withheld; Scharen-Guivel received 10,799,780 votes for and 278,243 votes withheld; and Hawkins received 8,376,696 votes for and 2,701,327 votes withheld. There were 709,490 broker non-votes for each director. The board will oversee a company that has delivered a remarkable 37% return to shareholders over the past year.
Second, stockholders ratified the selection of RSM US LLP as Iradimed's independent registered public accounting firm for the fiscal year ending December 31, 2025. The proposal received 11,775,729 votes for, 10,385 votes against, and 1,399 abstentions.
Third, stockholders approved an advisory resolution on the compensation of Iradimed's named executive officers. The vote tally was 10,777,171 in favor, 286,889 against, and 13,963 abstentions, with 709,490 broker non-votes.
The information in this article is based on a press release statement and the company's SEC filing. For deeper insights into Iradimed's financial health, valuation metrics, and growth potential, investors can access comprehensive analysis through InvestingPro, which offers detailed research reports and real-time financial data for over 1,400 US stocks.
In other recent news, Iradimed Corporation reported strong financial results for the first quarter of 2025, exceeding both earnings per share (EPS) and revenue expectations. The company achieved an EPS of $0.42, surpassing the forecasted $0.41, while revenue reached $19.5 million, above the anticipated $19.13 million. This marks the 15th consecutive quarter of record revenues for Iradimed, driven by an 11% year-over-year revenue increase, with domestic sales accounting for 82% of total revenue. Additionally, Iradimed has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new MRidium® 3870 IV Infusion Pump System, which is designed to improve patient safety during MRI procedures. The company plans to begin deploying this system at select healthcare facilities in the fourth quarter of 2025, with full commercial distribution expected in 2026. Iradimed's CEO, Roger Susi, expressed confidence in the company's operational plans, highlighting the importance of the new infusion pump in advancing MRI-compatible medical technology. The company also provided guidance for Q2 2025, projecting revenue between $19.7 million and $19.9 million, with GAAP EPS expected to range from $0.37 to $0.40.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.